Visit COVID-19 resources

[Skip to Content]

New Eye Journal Collection: Avastin and Wet AMD

Dec 03
2018

Eye, the journal of The Royal College of Ophthalmologists, has this week published their online collection drawing together papers published on Avastin and Wet AMD in 2018. Members will no doubt be aware of the issue, and ongoing work by the College in campaigning since 2012 for the use of Avastin in treatment for wet

  • 3 December 2018

Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy – (Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy, Published online: 2018-11-30; | doi:10.1038/s41433-018-0297-7)

Nov 30
2018

Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy, Published online: 30 November 2018; doi:10.1038/s41433-018-0297-7 Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital

  • 30 November 2018

Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both – (Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both, Published online: 2018-11-29; | doi:10.1038/s41433-018-0280-3)

Nov 29
2018

Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both Implications for pharmaceutical companies and clinicians from the <i>Bayer</i> v <i>NHS</i> judgement: an increasing budgetary focus for both, Published online: 29 November 2018; doi:10.1038/s41433-018-0280-3 Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an

  • 29 November 2018

Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease – (Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease, Published online: 2018-11-29; | doi:10.1038/s41433-018-0289-7)

Nov 29
2018

Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease, Published online: 29 November 2018;

  • 29 November 2018

Unique presentation of congenital cataract concurrent with microcornea, microphthalmia plus posterior capsule defect in monozygotic twins caused by a novel GJA8 mutation – (Unique presentation of congenital cataract concurrent with microcornea, microphthalmia plus posterior capsule defect in monozygotic twins caused by a novel GJA8 mutation, Published online: 2018-11-29; | doi:10.1038/s41433-018-0277-y)

Nov 29
2018

Unique presentation of congenital cataract concurrent with microcornea, microphthalmia plus posterior capsule defect in monozygotic twins caused by a novel GJA8 mutation Unique presentation of congenital cataract concurrent with microcornea, microphthalmia plus posterior capsule defect in monozygotic twins caused by a novel <i>GJA8</i> mutation, Published online: 29 November 2018; doi:10.1038/s41433-018-0277-y Unique presentation of congenital cataract

  • 29 November 2018